Earnings summaries and quarterly performance for ANGIODYNAMICS.
Executive leadership at ANGIODYNAMICS.
James Clemmer
Detailed
President and Chief Executive Officer
CEO
LP
Laura Piccinini
Detailed
Senior Vice President and General Manager, Cardiovascular and International
LW
Lawrence Weiss
Detailed
Senior Vice President, Chief Legal Officer and Corporate Secretary
ST
Stephen Trowbridge
Detailed
Executive Vice President and Chief Financial Officer
WN
Warren Nighan
Detailed
Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs
Board of directors at ANGIODYNAMICS.
Research analysts who have asked questions during ANGIODYNAMICS earnings calls.
Frank Takkinen
Lake Street Capital Markets
4 questions for ANGO
Also covers: AORT, AXGN, BBNX +17 more
YC
Yi Chen
H.C. Wainwright & Co.
4 questions for ANGO
Also covers: APDN, BLFS, BLTE +22 more
JY
John Young
Canaccord Genuity - Global Capital Markets
3 questions for ANGO
Also covers: CVRX, IRTC, LUNG +2 more
JY
Jon Young
Canaccord Genuity Group Inc.
3 questions for ANGO
Also covers: CBLL
SL
Steven Lichtman
Oppenheimer & Co. Inc.
3 questions for ANGO
Also covers: ALC, COO, DXCM +12 more
Bill Plovanic
Canaccord Genuity
2 questions for ANGO
Also covers: AORT, CBLL, DXCM +7 more
EH
Eduardo Han
H.C. Wainwright & Co.
2 questions for ANGO
Eduardo Martinez-Montes
H.C. Wainwright & Co., LLC
2 questions for ANGO
Also covers: BLFS, CDXC, CODX +8 more
Recent press releases and 8-K filings for ANGO.
AngioDynamics Highlights MedTech Growth and Announces CEO Retirement
ANGO
CEO Change
Guidance Update
Revenue Acceleration/Inflection
- AngioDynamics has undergone a five-year transformation to focus on a MedTech portfolio in cardiovascular disease and solid tumor cancer, achieving a five-year CAGR of approximately 25% in this segment.
- The company's key MedTech products, including Auryon for PAD, AlphaVac for PE, and NanoKnife for prostate cancer, are driving growth, with NanoKnife recently receiving CPT I code approval as of January 1, 2026.
- AngioDynamics is now generating positive EBITDA and expects to be cash flow positive for the fiscal year ending May 31, 2026, with zero debt on its balance sheet, and has raised its full-year guidance.
- CEO Jim Clemmer announced his retirement from the company this calendar year, with a search process initiated for his successor.
22 hours ago
AngioDynamics CEO Jim Clemmer Announces Retirement; Company Reports Strong MedTech Growth and Positive Financial Outlook
ANGO
CEO Change
Guidance Update
New Projects/Investments
- Jim Clemmer, CEO of AngioDynamics, announced his retirement from the company, effective later in calendar year 2026, after nearly 10 years in the role.
- AngioDynamics has undergone a five-year transformation, divesting non-core businesses to focus on its MedTech portfolio, which has achieved a 25% CAGR.
- The company's MedTech portfolio includes Auryon, which is up nearly 20% year-to-date , and NanoKnife, which received FDA clearance in December 2024 and a CPT-1 code on January 1, 2026, for intermediate-risk prostate cancer.
- AngioDynamics raised its full-year guidance and expects to be cash flow positive for the fiscal year ending May 31, 2026, with increasing EBITDA and free cash generation in subsequent years.
- The company plans to drive future growth through internal pipeline expansion into new markets such as BPH, DVT, and the coronary market, rather than through M&A.
22 hours ago
AngioDynamics Highlights MedTech Growth and CEO Retirement at J.P. Morgan Conference
ANGO
CEO Change
Product Launch
Revenue Acceleration/Inflection
- AngioDynamics has completed a five-year transformation to focus on its MedTech portfolio, which has achieved a 25% CAGR and now represents over 45% of total revenue, projected to exceed 50% by FY 2027.
- The company's MedTech products, including Auryon (projected to generate over $60 million in revenue this year) and NanoKnife (which received FDA indication in December 2024 and a CPT-1 code on January 1, 2026, for intermediate risk prostate cancer), are driving growth.
- AngioDynamics is expected to be cash flow positive for the fiscal year ending May 31, 2026, and currently holds zero debt.
- CEO Jim Clemmer announced his retirement from the company this calendar year, initiating a search for a new leader.
22 hours ago
AngioDynamics provides FY2026 financial outlook and strategic update at J.P. Morgan Healthcare Conference
ANGO
Guidance Update
New Projects/Investments
- AngioDynamics, Inc. President and CEO, James Clemmer, presented at the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026.
- The company increased its FY2026 financial guidance for Net Sales to $312 - $314 million and Adjusted EBITDA to +$8.0 - $10.0 million.
- AngioDynamics reported a strong balance sheet with $41.6 million in cash as of November 30, 2025, and zero debt.
- The company is focused on sustained profitable growth in key MedTech markets, including Prostate Care, Peripheral Artery Disease, and Venous Thromboembolism, supported by products like Auryon, AlphaVac, and NanoKnife.
1 day ago
AngioDynamics Reports Strong Q2 FY2026 Results, Raises Full-Year Guidance, and Announces CEO Retirement
ANGO
Earnings
Guidance Update
CEO Change
- AngioDynamics reported Q2 FY2026 revenue of $79.4 million, an 8.8% increase year-over-year, primarily driven by 13% growth in Med Tech revenue to $35.7 million.
- The company achieved an Adjusted EBITDA of $5.9 million in Q2 FY2026, nearly doubling the prior year's Q2, and improved its gross margin by 170 basis points to 56.4%.
- AngioDynamics raised its full-year FY2026 guidance for net sales to a range of $312-$314 million and Adjusted EBITDA to $8 million-$10 million.
- The company announced three regulatory milestones for its mechanical thrombectomy portfolio, including IDE approvals for the APEX Return and PAVE studies, and 510(k) clearance for a modified AlphaVac F1885 system.
- President and CEO Jim Clemmer announced his intention to retire, with a successor expected to be appointed during fiscal 2027.
Jan 6, 2026, 1:00 PM
AngioDynamics Reports Strong Q2 2026 Results, Raises Guidance, and Announces CEO Retirement
ANGO
Earnings
Guidance Update
CEO Change
- AngioDynamics reported strong Q2 fiscal year 2026 results, with revenue increasing 8.8% to $79.4 million and adjusted EBITDA nearly doubling year-over-year to $5.9 million.
- The company raised its full-year fiscal 2026 guidance, now expecting net sales in the range of $312-$314 million and adjusted EBITDA between $8 million-$10 million.
- Key product performance included Auryon's 18th consecutive quarter of double-digit growth (18.6% increase), AlphaVac's 40.2% year-over-year increase, and NanoKnife revenue growing 22.2%, primarily driven by prostate procedures.
- CEO Jim Clemmer announced his intention to retire, with a search for his successor underway, and the company confirmed the resolution of long-standing port patent litigation with C.R. Bard.
Jan 6, 2026, 1:00 PM
AngioDynamics Reports Strong Q2 FY26 Results, Raises Full-Year Guidance, and Announces CEO Retirement
ANGO
Earnings
Guidance Update
CEO Change
- AngioDynamics reported strong second quarter fiscal year 2026 results, with revenue growing 8.8% to $79.4 million and adjusted EBITDA nearly doubling year over year to $5.9 million.
- The company raised its full-year fiscal year 2026 guidance, now projecting net sales between $312-$314 million and adjusted EBITDA between $8 million-$10 million.
- Key product lines demonstrated robust growth, including Auryon with 18.6% growth and NanoKnife with 22.2% growth, while the mechanical thrombectomy portfolio achieved three significant regulatory milestones.
- CEO Jim Clemmer announced his intention to retire, with a successor expected to be appointed during fiscal year 2027.
- The U.S. Court of Appeals affirmed the invalidation of C.R. Bard's port patents, eliminating a potential $3 million payment by AngioDynamics.
Jan 6, 2026, 1:00 PM
AngioDynamics Reports Q2 FY 2026 Results, Updates Guidance, and Announces CEO Retirement
ANGO
Earnings
Guidance Update
CEO Change
- AngioDynamics reported net sales of $79.4 million for Q2 FY 2026, representing an 8.8% year-over-year growth. Med Tech segment sales grew by 13.0% to $35.7 million, and Med Device segment sales increased by 5.6% to $43.8 million.
- The company increased its full-year FY 2026 net sales guidance to $312 - $314 million (from $308 - $313 million) and Med Device Net Sales Growth guidance to +0-1% (from Flat). Adjusted EBITDA guidance was also increased to +$8.0 - $10.0 million (from +$6.0 - $10.0 million).
- Jim Clemmer, President and CEO, announced his intention to retire during fiscal 2027 upon the appointment of a successor, with a search committee established by the Board.
- AngioDynamics ended Q2 FY 2026 with $41.6 million in cash and zero debt, having generated approximately $4.7 million of cash in the quarter.
Jan 6, 2026, 1:00 PM
AngioDynamics Reports Strong Q2 FY 2026 Results and Raises Full-Year Guidance
ANGO
Earnings
Guidance Update
CEO Change
- AngioDynamics reported Q2 FY 2026 net sales of $79.4 million, an 8.8% increase year-over-year on a pro forma basis, driven by 13.0% growth in Med Tech net sales.
- For the quarter ended November 30, 2025, the company achieved adjusted EBITDA of $5.9 million and an adjusted loss per share of $0.00.
- AngioDynamics raised its full-year FY 2026 guidance for net sales to $312 - $314 million and Adjusted EBITDA to $8.0 - $10.0 million.
- The company ended the fiscal 2026 second quarter with $41.6 million in cash and cash equivalents and continues to expect to be cash flow positive for the full fiscal year 2026.
- Jim Clemmer will retire as President and CEO during fiscal year 2027, and the Board has initiated a comprehensive search for his successor.
Jan 6, 2026, 12:15 PM
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results and Updates Guidance
ANGO
Earnings
Guidance Update
CEO Change
- AngioDynamics reported net sales of $79.4 million for the second quarter of fiscal year 2026, an 8.8% increase pro forma year-over-year, driven by Med Tech net sales of $35.7 million, up 13.0%.
- The company achieved adjusted EBITDA of $5.9 million and an adjusted loss per share of $0.00 for the second quarter of fiscal year 2026.
- AngioDynamics raised its full-year fiscal year 2026 guidance for net sales to $312 - $314 million and Adjusted EBITDA to $8.0 - $10.0 million.
- Jim Clemmer announced his retirement as President and CEO during fiscal year 2027, with a search for his successor underway.
Jan 6, 2026, 11:00 AM
Quarterly earnings call transcripts for ANGIODYNAMICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more